Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
IMNN Imunon
1.610+0.020+1.26%
Trading Session
02/08 12:05 ET
High
1.650
Open
1.580
Turnover
34.00K
Low
1.580
Pre Close
1.590
Volume
20.91K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersTransCode Therapeutics (NASDAQ:RNAZ) stock moved upwards by 49.2% to $1.12 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 2.8 million shares
IMUNON Receives $1.6 Million From Sale of Its New Jersey Net Operating Losses
Non-dilutive funding strengthens balance sheet and extends current operating runway into 2025The sale of an additional $1.8 million of unused New Jersey NOLs expected in 2023 LAWRENCEVILLE, NJ, Jan.
IMUNON Enters Into Collaborative Research Agreement With The Wistar Institute's Vaccine & Immunotherapy Center to Research IMUNON's PLACCINE Vaccine Platform
LAWRENCEVILLE, NJ and PHILADELPHIA, PA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, and The Wistar Institute, a global leader in biomedical research
Imunon (NASDAQ:IMNN) Shares Down 1.8%
Imunon, Inc. (NASDAQ:IMNN – Get Rating) fell 1.8% during mid-day trading on Friday . The stock traded as low as $1.29 and last traded at $1.35. 43,140 shares traded hands during trading, a decline of
Imunon, Inc. - Common Stock's Return On Capital Employed Overview
Benzinga Pro data, Imunon, Inc. - Common Stock (NASDAQ:IMNN) reported Q3 sales of $125 thousand. Earnings fell to a loss of $6.15 million, resulting in a 1.74% decrease from last quarter. In Q2, Imuno
IMUNON Reports Inducement Grants Under NASDQ Listing Rule 5646(c)(4)
LAWRENCEVILLE, N.J., Dec. 14, 2022 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the
Imunon (NASDAQ:IMNN) Shares Down 2.8%
Shares of Imunon, Inc. (NASDAQ:IMNN – Get Rating) traded down 2.8% on Thursday . The company traded as low as $1.38 and last traded at $1.38. 20,449 shares traded hands during mid-day trading, a decl
IMUNON Presentation at World Vaccine & Immunotherapy Congress Highlights PLACCINE Preclinical Proof of Concept and Key Competitive Advantages
LAWRENCEVILLE, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, announces that Khursheed Anwer, Ph.D., the company's Executive Vice President and Chief
Watching Imunon, Zacks Small-Cap Research Sets $17 Price Valuation
Watching Imunon, Zacks Small-Cap Research Sets $17 Price Valuation
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's session, 107 stocks hit new 52-week lows. Key Facts About Today's 52-Week Lows: CrowdStrike Holdings (NASDAQ:CRWD) was the largest firm on a market cap basis to set a new 52-week
Company Overview
More
Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.
CEO： Ms. Corinne Le Goff, Pharm.D.
Market： NASDAQ
Listing Date： 02/08/2008
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet